The patent applications entitled, ‘Compositions to Effect Neuronal Growth,’ include three new compounds and also cover both structure and method claims for inducing neurogenesis and the growth of new neurons, both in-vitro and in-vivo.
First neurogenic patended compound of Neuralstem is now in Phase I trial evaluating pateints with Major depressive disorder.
The company further expects to begin Phase Ib trial in depressed patients this fall.
Neuralstem chairman and chief scientific officer Karl Johe said these patents cover additional new chemical entities from their neurogenic program and their potential clinical development pipeline.
"We believe that our portfolio of neurogenic compounds will be at the forefront of novel treatments for psychiatric and cognitive diseases that focus on neural regeneration, not just brain chemistry," Johe said.